PUBLIC COMPANY
save$JAZZJazz Pharmaceuticals plc
$JAZZ216.26+0.13%Dublin, IEupdated 18d ago
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
community read0 votes
🐶 often sniffed alongside
top 4pipeline
14
marketed
8
phase 3
0
catalysts ytd
5
approvals ytd
1
recalls ytd
0
Pipeline(14)
view full pipeline →pipeline depth14 products
3Phase 11Phase 28Marketed1pre_registration1Unknown
Marketed
(calcium oxybate + magnesium oxybate + potassium oxybate + sodium oxybate)
Cataplexy
Marketed(cytarabine hydrochloride + daunorubicin hydrochloride)
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
MarketedRylaze
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leuk…
MarketedSODIUM OXYBATE
Cataplexy
Marketedcannabidiol
Infantile Spasm (West Syndrome)
Cannabinoid receptor 1
Marketeddefibrotide sodium
Hepatic Veno-Occlusive Disease
Marketeddordaviprone hydrochloride
Glioma
Marketedlurbinectedin
Ewing Sarcoma
Phase 2cannabidivarin
Autism Spectrum Disorder (ASD)
Phase 1JZP-3507
Ependymoma
Phase 1JZP-898
Gastroesophageal (GE) Junction Carcinomas
Phase 1flezurafenib
Hematological Tumor
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase4A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy
- phase1A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants
- phase3ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
- phase2A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
- phase1A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1
- phase4A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
- phase2A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
- —To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
🐶 Hiring Signal
News
- 8 companies hiring in North Carolina nowLooking for a biopharma role in North Carolina? Jobs on BioSpace increased significantly year over year in October. Check out the open positions posted now for life sciences professionals like you.biospace · 2d ago
- BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’BioNTech has agreed to pay $205 million to purchase an FDA priority review voucher to support a future filing of a drug in its “late-stage oncology pipeline.” Fierce breaks down which candidate is…fiercebiotech · 9d ago
- BioSpace 2027 Best Places to Work shines light on most admired employersThe list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.biospace · 10d ago
- 6 potential blockbusters that could pave China’s path to 2030 ambitionsIn its latest five-year plan, China has set its sights on developing five drugs that could each rake in more than $1 billion globally by 2030. Experts say it's well on its way, with two medications…biospace · 16d ago
- New biotech Setara forms with $90M to take on Jazz’s bonus rare disease programsSetara Biosciences has formed around a handful of assets from Actio Biosciences, which was acquired by Jazz Pharmaceuticals earlier this year.biospace · 21d ago
- Setara gets $90M to continue rare disease pipeline spun out of Jazz's Actio dealAfter shipping its precision epilepsy drug to Jazz Pharmaceuticals, Actio Biosciences has spun out the remainder of its genetics-driven pipeline into a new company called Setara Biosciences. Setara…endpoints · 21d ago
- With Setara, the team behind Actio opens its second actThe fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy prog…biopharma_dive · 21d ago
- Jazz's $820M Actio buyout gives rise to Setara, armed with $90M series ASetara Biosciences, a privately held spinout formed following Jazz Pharmaceuticals' acquisition of Actio Biosciences in September, has raised $90 million in series A financing to advance its clinic…fiercebiotech · 22d ago
- Aspen, Bambusa target $135M IPOs; AstraZeneca vs. Takeda in gastric cancer ADCsPlus news about Hutchmed, Johnson & Johnson, Jazz Pharmaceuticals, Novartis, Roche and Oruka Therapeutics. Aspen, Bambusa both eye $135M IPOs: Aspen Neuroscience plans to sell 9.38 million shares {…endpoints · 25d ago
- Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engagerRoche will pay Zymeworks $55 million upfront plus another $40 million once the partnership asset enters Phase 1b development and up to $718 million in additional milestones.biospace · 28d ago
Data sources
last refreshed 5m ago
Found something off?
comments(0)
5-min edit window · permanent after that